Insider Transactions in Q1 2021 at Ultragenyx Pharmaceutical Inc. (RARE)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 08
2021
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,000
-18.13%
|
$360,000
$120.69 P/Share
|
|
Mar 02
2021
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
707
-2.48%
|
$97,566
$138.16 P/Share
|
|
Mar 01
2021
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Indirect |
30,000
-1.29%
|
$4,230,000
$141.8 P/Share
|
|
Mar 01
2021
|
Emil D Kakkis President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,342
-2.67%
|
$2,320,564
$142.47 P/Share
|
|
Mar 01
2021
|
Emil D Kakkis President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
33,453
+2.69%
|
-
|
|
Mar 01
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,543
-10.4%
|
$626,934
$138.18 P/Share
|
|
Mar 01
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,136
+10.97%
|
-
|
|
Mar 01
2021
|
Mardi Dier CFO & Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+10.78%
|
-
|
|
Mar 01
2021
|
Dennis Karl Huang |
SELL
Open market or private sale
|
Direct |
4,255
-9.45%
|
$587,190
$138.18 P/Share
|
|
Mar 01
2021
|
Dennis Karl Huang |
BUY
Grant, award, or other acquisition
|
Direct |
10,136
+10.7%
|
-
|
|
Mar 01
2021
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,470
-7.97%
|
$340,860
$138.17 P/Share
|
|
Mar 01
2021
|
Erik Harris EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,136
+15.14%
|
-
|
|
Mar 01
2021
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
732
-4.24%
|
$101,016
$138.17 P/Share
|
|
Mar 01
2021
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,560
+8.28%
|
-
|
|
Mar 01
2021
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,970
-11.61%
|
$547,860
$138.17 P/Share
|
|
Mar 01
2021
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,136
+13.81%
|
-
|
|
Mar 01
2021
|
John Richard Pinion |
SELL
Open market or private sale
|
Direct |
6,198
-10.98%
|
$855,324
$138.17 P/Share
|
|
Mar 01
2021
|
John Richard Pinion |
BUY
Grant, award, or other acquisition
|
Direct |
10,136
+8.6%
|
-
|
|
Mar 01
2021
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
4,572
-4.09%
|
$630,936
$138.17 P/Share
|
|
Mar 01
2021
|
Thomas Richard Kassberg CBO & EVP |
BUY
Grant, award, or other acquisition
|
Direct |
10,136
+4.44%
|
-
|
|
Feb 23
2021
|
William Aliski Director |
SELL
Bona fide gift
|
Direct |
1,000
-1.52%
|
-
|
|
Feb 19
2021
|
William Aliski Director |
SELL
Open market or private sale
|
Direct |
7,500
-10.25%
|
$1,117,500
$149.01 P/Share
|
|
Feb 19
2021
|
William Aliski Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+9.29%
|
$727,500
$97.85 P/Share
|
|
Jan 30
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,243
-6.27%
|
$314,020
$140.36 P/Share
|
|
Jan 15
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
25,000
-41.13%
|
$3,475,000
$139.18 P/Share
|
|
Jan 15
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+29.14%
|
$1,375,000
$55.0 P/Share
|
|
Jan 07
2021
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
4,000
-20.29%
|
$560,000
$140.65 P/Share
|
|
Jan 07
2021
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+16.37%
|
$84,000
$21.0 P/Share
|
|
Jan 04
2021
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Indirect |
30,000
-1.27%
|
$4,080,000
$136.9 P/Share
|